Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis

Molecular Carcinogenesis

Volumn 48, Issue 6, 2009, Pages 553-562

  Huang, Xinqiang ^a,b   Yang, Chaofeng ^a   Jin, Chengliu ^a   Luo, Yongde ^a   Wang, Fen ^a   McKeehan, Wallace L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholesterol metabolism; FGF; Hepatocellular carcinoma; Liver adenoma; Metabolism; Tyrosine kinase signaling

Indexed keywords

BILE ACID; CHOLESTEROL; CYCLIN D1; DIETHYLNITROSAMINE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P27; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHOLESTEROL BILE LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; GENE EXPRESSION; HEPATOMA CELL; HISTOPATHOLOGY; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL PROLIFERATION; DNA PRIMERS; FIBROBLAST GROWTH FACTOR 4; GENE EXPRESSION PROFILING; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

MUS;

EID: 65749086156     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20494     Document Type: Article

References (50)

1. McKeehan WL, Wang F, Kan M. The heparan sulfate- fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998;59:135-176.
2. Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 1999; 274:15947-15952. (Pubitemid 129518960)
3. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687-26695.
4. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci 1999;4:D165-D177.
5. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-197.
6. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997;57:5369-5378. (Pubitemid 27516376)
7. Jin C, McKeehan K, Guo W, et al. Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res 2003;63:8784-8790.
8. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000;275:15482-15489.
9. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-225.
10. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-1635.
11. Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 56:2501-2510. (Pubitemid 47523257)
12. Hu Z, Evarts RP, Fujio K, Marsden ER, Thorgeirsson SS. Expression of fibroblast growth factor receptors flg and bek during hepatic ontogenesis and regeneration in the rat. Cell Growth Differ 1995;6:1019-1025.
13. Hu Z, Evarts RP, Fujio K, et al. Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis 1996;17:931-938.
14. Yu C, Wang F, Jin C, Wu X, Chan WK, McKeehan WL. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol 2002;161: 2003-2010.
15. Yu C, Wang F, Jin C, Huang X, McKeehan WL. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 2005;280:17707-17714. (Pubitemid 41389008)
16. Kin M, Sata M, Ueno T, et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997;27:677-687.
17. Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996;24:198-205. (Pubitemid 26249434)
18. Huang X, Yu C, Jin C, et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res 2006;66:1481-1490.
19. Kan M, DiSorbo D, Hou JZ, Hoshi H, Mansson PE, McKeehan WL. High and low affinity binding of heparin-binding growth factor to a 130-kDa receptor correlates with stimulation and inhibition of growth of a differentiated human hepatoma cell. J Biol Chem 1988;263:11306-11313. (Pubitemid 18202951)
20. Huang X, Yu C, Jin C, et al. Forced expression of hepatocytespecific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006;45:934-942.
21. Ricol D, Cappellen D, El Marjou A, et al. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999;18:7234-7243.
22. Zhang Y, Wang H, Toratani S, et al. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci USA 2001;98:11336-11340.
23. Jang JH, Shin KH, Park YJ, Lee RJ, McKeehan WL, Park JG. Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res 2000;60:4049-4052. (Pubitemid 30636582)
24. Jang JH. Reciprocal relationship in gene expression between FGFR1 and FGFR3: Implication for tumorigenesis. Oncogene 2005;24:945-948.
25. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002;62:840-847.
26. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004;10: 6169-6178. (Pubitemid 39287523)
27. Jaakkola S, Salmikangas P, Nylund S, et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993;54:378-382.
28. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146:1145-1153. (Pubitemid 40289303)
29. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295-2307.
30. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27:85-97.
31. Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 1998;125:3615-3623. (Pubitemid 28469962)
32. Takaishi S, Sawada M, Morita Y, Seno H, Fukuzawa H, Chiba T. Identification of a novel alternative splicing of human FGF receptor 4: Soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 2000;267:658-662.
33. Ezzat S, Zheng L, Yu S, Asa SL. A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem Biophys Res Commun 2001; 287:60-65. (Pubitemid 32912463)
34. Morita K, Takano K, Yasufuku-Takano J, et al. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2008;68:435-441.
35. Marks JL, McLellan MD, Zakowski MF, et al. Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2007;2:e426.
36. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007; 67:863-867. (Pubitemid 46270737)
37. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729-735.
38. Molina R, Chen B, Rose B, et al. Inhibition of experimental tumor models achieved through systemic elevation of FGF19 in vivo. AACR Meeting Abstracts 2004;2004:1200-c-1201.
39. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptindeficient diabetes. Endocrinology 2004;145:2594-2603.
40. Wang JK, Gao G, Goldfarb M. Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol Cell Biol 1994;14:181-188. (Pubitemid 24013080)
41. Vainikka S, Joukov V, Wennstrom S, Bergman M, Pelicci PG, Alitalo K. Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J Biol Chem 1994;269:18320-18326.
42. Shaoul E, Reich-Slotky R, Berman B, Ron D. Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene 1995;10:1553-1561.
43. Raffioni S, Thomas D, Foehr ED, Thompson LM, Bradshaw RA. Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. Proc Natl Acad Sci USA 1999;96:7178-7183. (Pubitemid 29299635)
44. Kwiatkowski BA, Kirillova I, Richard RE, Israeli D, Yablonka- Reuveni Z. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation. J Cell Physiol 2008;215:803-817.
45. Moller MB. P27 in cell cycle control and cancer. Leuk Lymphoma 2000;39:19-27. (Pubitemid 30657804)
46. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877-880. (Pubitemid 26154591)
47. Freeman KW, Gangula RD, Welm BE, et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteoponti induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 2003;63: 6237-6243.
48. Xian W, Schwertfeger KL, Rosen JM. Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. Mol Endocrinol 2007;21:987-1000. (Pubitemid 46984736)
49. Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12:559-571.
50. Ishikawa T, Fidge N. Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR 1339 to rats. J Lipid Res 1979;20:254-264. (Pubitemid 9150673)